JP7042548B2 - Ｍａｇｌ阻害剤の結晶形態 - Google Patents

Ｍａｇｌ阻害剤の結晶形態 Download PDF

Info

Publication number
JP7042548B2
JP7042548B2 JP2019523672A JP2019523672A JP7042548B2 JP 7042548 B2 JP7042548 B2 JP 7042548B2 JP 2019523672 A JP2019523672 A JP 2019523672A JP 2019523672 A JP2019523672 A JP 2019523672A JP 7042548 B2 JP7042548 B2 JP 7042548B2
Authority
JP
Japan
Prior art keywords
compound
theta
crystalline
patient
hexafluoropropane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019523672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537596A5 (enExample
JP2019537596A (ja
Inventor
エー． グライス，シェリル
ケー． ジョーンズ，トッド
ジー． グリム，カート
ロレイン ブランクマン，ジャクリーン
ロドニー ビールス，チャニング
Original Assignee
ルンドベック ラ ホーヤ リサーチ センター，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルンドベック ラ ホーヤ リサーチ センター，インク． filed Critical ルンドベック ラ ホーヤ リサーチ センター，インク．
Publication of JP2019537596A publication Critical patent/JP2019537596A/ja
Publication of JP2019537596A5 publication Critical patent/JP2019537596A5/ja
Priority to JP2022035398A priority Critical patent/JP7350117B2/ja
Application granted granted Critical
Publication of JP7042548B2 publication Critical patent/JP7042548B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019523672A 2016-11-16 2017-11-15 Ｍａｇｌ阻害剤の結晶形態 Expired - Fee Related JP7042548B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022035398A JP7350117B2 (ja) 2016-11-16 2022-03-08 Ｍａｇｌ阻害剤の結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423126P 2016-11-16 2016-11-16
US62/423,126 2016-11-16
PCT/US2017/061875 WO2018093953A1 (en) 2016-11-16 2017-11-15 Crystalline forms of a magl inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022035398A Division JP7350117B2 (ja) 2016-11-16 2022-03-08 Ｍａｇｌ阻害剤の結晶形態

Publications (3)

Publication Number Publication Date
JP2019537596A JP2019537596A (ja) 2019-12-26
JP2019537596A5 JP2019537596A5 (enExample) 2020-12-24
JP7042548B2 true JP7042548B2 (ja) 2022-03-28

Family

ID=62145805

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019523672A Expired - Fee Related JP7042548B2 (ja) 2016-11-16 2017-11-15 Ｍａｇｌ阻害剤の結晶形態
JP2022035398A Active JP7350117B2 (ja) 2016-11-16 2022-03-08 Ｍａｇｌ阻害剤の結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022035398A Active JP7350117B2 (ja) 2016-11-16 2022-03-08 Ｍａｇｌ阻害剤の結晶形態

Country Status (38)

Country Link
US (2) US11142517B2 (enExample)
EP (2) EP3964503B1 (enExample)
JP (2) JP7042548B2 (enExample)
KR (1) KR102508739B1 (enExample)
CN (2) CN110291083B (enExample)
AU (1) AU2017361257B2 (enExample)
BR (1) BR112019010003A2 (enExample)
CA (1) CA3043610A1 (enExample)
CL (1) CL2019001340A1 (enExample)
CO (1) CO2019005045A2 (enExample)
CR (1) CR20190242A (enExample)
CY (1) CY1124870T1 (enExample)
DK (1) DK3541807T3 (enExample)
DO (1) DOP2019000120A (enExample)
EA (1) EA201991086A1 (enExample)
EC (1) ECSP19035171A (enExample)
ES (2) ES2900016T3 (enExample)
GE (1) GEP20237559B (enExample)
HR (2) HRP20211863T1 (enExample)
HU (2) HUE056973T2 (enExample)
IL (1) IL266548A (enExample)
JO (1) JOP20190109B1 (enExample)
LT (1) LT3541807T (enExample)
MA (2) MA58133B1 (enExample)
MX (2) MX389459B (enExample)
MY (1) MY199386A (enExample)
NI (1) NI201900053A (enExample)
PE (1) PE20191239A1 (enExample)
PH (1) PH12019501068A1 (enExample)
PL (2) PL3541807T3 (enExample)
PT (1) PT3541807T (enExample)
RS (2) RS62665B1 (enExample)
SI (1) SI3541807T1 (enExample)
SM (2) SMT202100675T1 (enExample)
TN (1) TN2019000151A1 (enExample)
UA (1) UA124585C2 (enExample)
WO (1) WO2018093953A1 (enExample)
ZA (1) ZA201903093B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508407A (ja) 2012-01-06 2015-03-19 アビデ セラピューティクス，インク． カルバメート化合物およびその製造および使用
CN107849021A (zh) 2015-05-11 2018-03-27 阿比德治疗公司 治疗炎症或神经性疼痛的方法
JP7042804B2 (ja) 2016-09-19 2022-03-28 ルンドベック ラ ホーヤ リサーチ センター，インク． ピペラジンカルバメート、及びその製造と使用の方法
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
MA58133B1 (fr) 2016-11-16 2024-02-29 H Lundbeck As Une forme cristalline d'un inhibiteur de magl
WO2018093950A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
AU2018271876B2 (en) 2017-05-23 2021-10-21 H. Lundbeck A/S. Pyrazole MAGL inhibitors
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
PE20200664A1 (es) 2017-08-29 2020-06-11 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso
US11332453B2 (en) 2018-05-15 2022-05-17 H. Lundbeck A/S MAGL inhibitors
CA3106510A1 (en) * 2018-07-19 2020-01-23 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
EP4474017A3 (en) 2018-08-13 2025-02-26 F. Hoffmann-La Roche AG New heterocyclic compounds
MX2021008865A (es) * 2019-01-25 2021-10-26 H Lundbeck As Inhibidores de magl para usarse para tratar enfermedades antecedentes.
US20210147367A1 (en) * 2019-11-15 2021-05-20 Lundbeck La Jolla Research Center, Inc. Crystalline forms of a magl inhibitor
MX2022013224A (es) * 2020-04-21 2022-11-14 H Lundbeck As Sintesis de un inhibidor de la monoacilglicerol lipasa.
WO2023092079A1 (en) * 2021-11-19 2023-05-25 Bryant Cynthia W Use of cannabinoid compounds to treat gastrointestinal disorders
EP4457213A4 (en) 2021-12-29 2025-12-17 Psy Therapeutics Inc INHIBITION OF MONOACYLGLYCEROL LIPASE (MAGL)
WO2023213854A1 (en) 2022-05-04 2023-11-09 H. Lundbeck A/S Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor.
CN117665187B (zh) * 2023-11-23 2024-08-16 宁波大红鹰药业股份有限公司 一种舒林酸中间体杂质的测定方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508407A (ja) 2012-01-06 2015-03-19 アビデ セラピューティクス，インク． カルバメート化合物およびその製造および使用
WO2015164160A1 (en) 2014-04-21 2015-10-29 Merck Sharp & Dohme Corp. Pharmaceutical salts of an orexin receptor antagonist
WO2016183097A1 (en) 2015-05-11 2016-11-17 Abide Therapeutics, Inc. Methods of treating inflammation or neuropathic pain
WO2017143283A1 (en) 2016-02-19 2017-08-24 Abide Therapeutics, Inc. Radiolabeled monoacylglycerol lipase occupancy probe

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
DE69222847T3 (de) 1991-04-16 2005-09-15 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung einer festen dispersion
CA2122479C (en) 1991-11-22 1998-08-25 Richard John Dansereau Risedronate delayed-release compositions
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
EP0665010B1 (en) 1992-10-16 2002-09-11 Nippon Shinyaku Company, Limited Method of manufacturing wax matrices
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
CA2220451A1 (en) 1995-05-17 1996-11-21 Cedars-Sinai Medical Center Methods and compositions for improving digestion and absorption in the small intestine
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
CN1461218A (zh) 2000-12-18 2003-12-10 诺瓦提斯公司 阿洛地平和贝那普利的治疗组合
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2003070247A1 (en) 2002-02-20 2003-08-28 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
UA90708C2 (ru) 2005-02-25 2010-05-25 Ф. Хоффманн-Ля Рош Аг Таблетки с улучшенной дисперсностью лекарственного вещества
MX336930B (es) 2005-11-28 2016-02-05 Marinus Pharmaceuticals Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
EP1938804A1 (en) 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
FR2938341A1 (fr) 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
CN101530399B (zh) 2009-04-15 2011-01-26 江苏中兴药业有限公司 一种水飞蓟宾固体自乳化片
CA2866302A1 (en) 2012-03-19 2013-09-26 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
WO2013159095A1 (en) 2012-04-20 2013-10-24 Anderson Gaweco Ror modulators and their uses
FI2914248T4 (fi) 2012-11-02 2023-12-19 Vertex Pharma Farmaseuttisia koostumuksia cftr-välitteisten tautien hoitamiseksi
TW201446286A (zh) 2013-01-31 2014-12-16 Gilead Pharmasset Llc 抗病毒化合物之固態分散調製劑
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
WO2015003002A1 (en) 2013-07-03 2015-01-08 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
US20150064252A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
CN103893258B (zh) 2013-12-05 2017-09-29 人福医药集团股份公司 含有广金钱草总黄酮的口服固体制剂及其应用
WO2015179559A2 (en) * 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2016149401A2 (en) 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
WO2018093950A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
MA58133B1 (fr) 2016-11-16 2024-02-29 H Lundbeck As Une forme cristalline d'un inhibiteur de magl

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508407A (ja) 2012-01-06 2015-03-19 アビデ セラピューティクス，インク． カルバメート化合物およびその製造および使用
WO2015164160A1 (en) 2014-04-21 2015-10-29 Merck Sharp & Dohme Corp. Pharmaceutical salts of an orexin receptor antagonist
WO2016183097A1 (en) 2015-05-11 2016-11-17 Abide Therapeutics, Inc. Methods of treating inflammation or neuropathic pain
WO2017143283A1 (en) 2016-02-19 2017-08-24 Abide Therapeutics, Inc. Radiolabeled monoacylglycerol lipase occupancy probe

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AITIPAMULA, Srinivasulu et al.，Polymorphs, Salts, and Cocrystals: What's in a Name?，Crystal Growth and Design，2014年04月12日，vol.12，pp/2147-2152
STEPHEN M BERGE; LYLE D BIGHLEY; DONALD C MONKHOUSE，PHARMACEUTICAL SALTS，JOURNAL OF PHARMACEUTICAL SCIENCES，米国，AMERICAN PHARMACEUTICAL ASSOCIATION，1977年01月，VOL:66, NR:1，PAGE(S):1 - 19，http://dx.doi.org/10.1002/jps.2600660104
平山令明編，有機化合物結晶作製ハンドブック －原理とノウハウ－，丸善株式会社，2008年07月25日，p.57-84
芹澤一英，医薬品の多形現象と晶析の化学，2002年，p.273,278,305-17

Also Published As

Publication number Publication date
CA3043610A1 (en) 2018-05-24
AU2017361257A1 (en) 2019-05-30
PH12019501068A1 (en) 2019-08-19
CL2019001340A1 (es) 2019-10-04
RS65016B1 (sr) 2024-01-31
SI3541807T1 (sl) 2022-01-31
DOP2019000120A (es) 2019-09-30
CY1124870T1 (el) 2022-11-25
EP3541807B1 (en) 2021-09-29
PL3541807T3 (pl) 2022-01-17
IL266548A (en) 2019-07-31
CR20190242A (es) 2019-07-09
JOP20190109B1 (ar) 2022-09-15
SMT202300494T1 (it) 2024-01-10
PL3964503T3 (pl) 2024-04-02
CN115093382A (zh) 2022-09-23
MX2019005767A (es) 2019-12-05
WO2018093953A1 (en) 2018-05-24
RU2019116689A (ru) 2020-12-17
HUE064559T2 (hu) 2024-03-28
US11142517B2 (en) 2021-10-12
HRP20211863T1 (hr) 2022-03-04
JP7350117B2 (ja) 2023-09-25
PT3541807T (pt) 2021-12-09
CO2019005045A2 (es) 2019-05-31
ES2900016T3 (es) 2022-03-15
US20220235037A1 (en) 2022-07-28
BR112019010003A2 (pt) 2019-08-20
DK3541807T3 (da) 2021-12-06
EP3541807A4 (en) 2020-04-22
HRP20231697T1 (hr) 2024-03-15
EP3964503B1 (en) 2023-11-08
MA46866B1 (fr) 2021-11-30
MA46866A (fr) 2021-06-02
EP3964503C0 (en) 2023-11-08
ES2966939T3 (es) 2024-04-25
KR102508739B1 (ko) 2023-03-09
CN110291083B (zh) 2022-06-17
US20200190063A1 (en) 2020-06-18
EP3964503A1 (en) 2022-03-09
LT3541807T (lt) 2021-12-27
NI201900053A (es) 2019-10-30
KR20190077561A (ko) 2019-07-03
MX389459B (es) 2025-03-20
RS62665B1 (sr) 2021-12-31
ECSP19035171A (es) 2019-05-31
ZA201903093B (en) 2020-11-25
UA124585C2 (uk) 2021-10-13
MY199386A (en) 2023-10-25
PE20191239A1 (es) 2019-09-16
JOP20190109A1 (ar) 2019-05-09
JP2022084717A (ja) 2022-06-07
EP3541807A1 (en) 2019-09-25
AU2017361257B2 (en) 2022-02-10
US11993588B2 (en) 2024-05-28
SMT202100675T1 (it) 2022-01-10
HUE056973T2 (hu) 2022-04-28
MA58133B1 (fr) 2024-02-29
MX2022000249A (es) 2022-02-03
CN110291083A (zh) 2019-09-27
GEP20237559B (en) 2023-10-25
RU2019116689A3 (enExample) 2021-02-26
EA201991086A1 (ru) 2019-11-29
TN2019000151A1 (en) 2020-10-05
NZ753241A (en) 2021-06-25
JP2019537596A (ja) 2019-12-26

Similar Documents

Publication Publication Date Title
JP7350117B2 (ja) Ｍａｇｌ阻害剤の結晶形態
JP7641320B2 (ja) ｓＧＣ刺激薬を含んでなる固体分散剤
JP2025026857A (ja) 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
TW202330485A (zh) 用於治療或預防痛風或高尿酸血症之化合物的結晶形式
RU2799564C2 (ru) Кристаллические формы ингибитора magl
HK40069310B (en) A crystalline form of a magl inhibitor
HK40069310A (en) A crystalline form of a magl inhibitor
AU2018325267B2 (en) Crystalline forms of compounds for preventing or treating sensory hair cell death
HK40009165B (en) A crystalline form of a magl inhibitor
HK40009165A (en) A crystalline form of a magl inhibitor
EA041551B1 (ru) Кристаллические формы ингибитора magl
NZ753241B2 (en) Crystalline forms of a magl inhibitor
JP2025524598A (ja) Ｓ１ｐ受容体モジュレーターの結晶形態

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190730

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20190730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220311

R150 Certificate of patent or registration of utility model

Ref document number: 7042548

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees